Us Congress 2023-2024 Regular Session

Us Congress Senate Bill SB2176

Introduced
6/22/23  

Caption

Therapeutic Fraud Prevention Act of 2023

Impact

The bill's enactment will significantly alter the landscape of mental health practices by creating legal ramifications for those who engage in conversion therapy. By making it unlawful to offer such treatments, the bill seeks to protect the mental and physical well-being of individuals who identify as LGBTQ. It underscores the recognition that being LGBTQ is not a disorder or lifestyle choice that can be changed through therapy, thus aligning legal definitions with professional mental health standards. Furthermore, it opens avenues for state attorneys general to take civil action against violators, thereby enhancing consumer protection.

Summary

Senate Bill 2176, known as the Therapeutic Fraud Prevention Act of 2023, aims to prohibit commercial sexual orientation conversion therapy. This legislation arises from a growing consensus among mental health professionals that such practices are not only ineffective but also harmful. The bill establishes a legal framework to prevent individuals from being subjected to therapies that attempt to change their sexual orientation or gender identity. This includes defining conversion therapy and outlining the implications for those who provide such services for monetary compensation.

Contention

Despite the bill's intended protective measures, there may be contentious debates surrounding its enforcement and implications for freedom of expression. Proponents argue that it is essential for public health and safety, ensuring that individuals are not misled by pseudo-scientific practices. Conversely, opponents could raise concerns about potential overreach or limitations on personal or religious freedoms, particularly among groups that might view conversion therapy as part of their belief system. As such, the bill could become a focal point for wider discussions about LGBTQ rights and health policy.

Companion Bills

US HB4340

Same As Therapeutic Fraud Prevention Act of 2023

Previously Filed As

US HB4340

Therapeutic Fraud Prevention Act of 2023

US SB1663

Therapeutic Fraud Prevention Act of 2025

US HB3243

Therapeutic Fraud Prevention Act of 2025

US HB3850

Pride In Mental Health Act of 2023

US HR568

Original LGBTQIA+ Pride Month Resolution of 2023

US HB4273

LGBTQI+ and Women’s History Education Act of 2023

US SB1007

International Human Rights Defense Act of 2023

US HB1833

International Human Rights Defense Act of 2023

US SB3949

Pride In Mental Health Act of 2024

US HB3757

Pride In Mental Health Act of 2025

Similar Bills

US SB1631

Safeguarding the Homeland from the Threats Posed by Unmanned Aircraft Systems Act of 2023

US HB4333

Safeguarding the Homeland from the Threats Posed by Unmanned Aircraft Systems Act of 2023

US SB1170

Project Safe Childhood Act

US HB3758

EQUAL Defense Act of 2023 Ensuring Quality Access to Legal Defense Act of 2023

US HB568

SAFE Act Save Americans from the Fentanyl Emergency Act

US SB1364

Foreign Agents Disclosure and Registration Enhancement Act of 2023

US SB1141

HALT Fentanyl Act Halt All Lethal Trafficking of Fentanyl Act

US HB467

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This bill places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Additionally, the bill establishes a new, alternative registration process for schedule I research that is funded by the Department of Health and Human Services or the Department of Veterans Affairs or that is conducted under an investigative new drug exemption from the Food and Drug Administration. The bill also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.